Christopher Ridley, a spokesperson for Moderna, said the state legislative efforts are largely a product of ...

The cutting-edge technology used in COVID-19 shots may lead to new treatments for other diseases. But some conservatives are ...

Fintel reports that on March 13, 2025, Citigroup initiated coverage of Moderna (NasdaqGS:MRNA) with a Neutral recommendation.

The National Institutes of Health is terminating dozens of studies examining why people are hesitant about vaccines and how ...

The National Institutes of Health is terminating dozens of studies examining why people are hesitant about vaccines and how ...

On the five-year anniversary of the Covid pandemic, a Times reporter, Apoorva Mandavilli, looks back at the success of, and the backlash to, the mRNA vaccine. There’s no question that this ...

Vaccine skeptics have long-since leveraged the rapid roll out of mRNA vaccines to add fuel to heated arguments surrounding vaccine safety. As a result, a growing share of the public is wary of ...

Unlock comprehensive insights into our analysis of Moderna stock here. NasdaqGS:MRNA Earnings Per Share Growth as at Mar 2025 Over the past five years, Moderna's total return, including share ...

Moderna (NasdaqGS:MRNA) recently faced significant legal challenges with five international lawsuits from Genevant Sciences and Arbutus Biopharma targeting its LNP technology used in products like ...

Moderna – at the moment embroiled in a patent dispute with Pfizer and BioNTech over mRNA intellectual property – is also testing a vaccine that combines COVID-19 and flu in a single jab in a ...

GSK has upgraded its longstanding alliance with CureVac on mRNA-based vaccines for respiratory infections, paying €400 million ($429 million) upfront for global rights to its influenza and COVID ...